Through in-licensing from or collaboration with big pharma/biotech companies and/or academic institutions, we have established a robust and science-driven portfolio that targets the underlying causes of the various orphan diseases with few or no approved options. Our focus is on first-in-class or best-in-class therapeutics that will truly bring meaningful and/or life-saving benefits to patients. We are also leveraging sponsored collaboration and research with universities to help de-risk potential projects before their adoption into our pipeline.